BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31517054)

  • 1. Antibodies to the conserved region of the M protein and a streptococcal superantigen cooperatively resolve toxic shock-like syndrome in HLA-humanized mice.
    Pandey M; Calcutt A; Ozberk V; Chen Z; Croxen M; Powell J; Langshaw E; Mills JL; Jen FE; McCluskey J; Robson J; Tyrrell GJ; Good MF
    Sci Adv; 2019 Sep; 5(9):eaax3013. PubMed ID: 31517054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superantigens and streptococcal toxic shock syndrome.
    Proft T; Sriskandan S; Yang L; Fraser JD
    Emerg Infect Dis; 2003 Oct; 9(10):1211-8. PubMed ID: 14609454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Streptococcus pyogenes: Insight into the function of the streptococcal superantigens.
    Sriskandan S; Faulkner L; Hopkins P
    Int J Biochem Cell Biol; 2007; 39(1):12-9. PubMed ID: 17029999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lethal shock induced by streptococcal pyrogenic exotoxin A in mice transgenic for human leukocyte antigen-DQ8 and human CD4 receptors: implications for development of vaccines and therapeutics.
    Welcher BC; Carra JH; DaSilva L; Hanson J; David CS; Aman MJ; Bavari S
    J Infect Dis; 2002 Aug; 186(4):501-10. PubMed ID: 12195377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome.
    Roggiani M; Stoehr JA; Olmsted SB; Matsuka YV; Pillai S; Ohlendorf DH; Schlievert PM
    Infect Immun; 2000 Sep; 68(9):5011-7. PubMed ID: 10948118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of circulating bacterial superantigen and lymphotoxin-alpha in patients with streptococcal toxic-shock syndrome.
    Sriskandan S; Moyes D; Cohen J
    Lancet; 1996 Nov; 348(9037):1315-6. PubMed ID: 8909404
    [No Abstract]   [Full Text] [Related]  

  • 7. Superantigenic activity of emm3 Streptococcus pyogenes is abrogated by a conserved, naturally occurring smeZ mutation.
    Turner CE; Sommerlad M; McGregor K; Davies FJ; Pichon B; Chong DL; Farzaneh L; Holden MT; Spratt BG; Efstratiou A; Sriskandan S
    PLoS One; 2012; 7(10):e46376. PubMed ID: 23049698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bacterial superantigen streptococcal mitogenic exotoxin Z is the major immunoactive agent of Streptococcus pyogenes.
    Unnikrishnan M; Altmann DM; Proft T; Wahid F; Cohen J; Fraser JD; Sriskandan S
    J Immunol; 2002 Sep; 169(5):2561-9. PubMed ID: 12193726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project.
    Watanabe-Ohnishi R; Low DE; McGeer A; Stevens DL; Schlievert PM; Newton D; Schwartz B; Kreiswirth B; Kotb M
    J Infect Dis; 1995 Jan; 171(1):74-84. PubMed ID: 7798684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft-tissue infection induced by Streptococcus pyogenes.
    Ramachandran G; Tulapurkar ME; Harris KM; Arad G; Shirvan A; Shemesh R; Detolla LJ; Benazzi C; Opal SM; Kaempfer R; Cross AS
    J Infect Dis; 2013 Jun; 207(12):1869-77. PubMed ID: 23493729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Streptococcal superantigen-induced expansion of human tonsil T cells leads to altered T follicular helper cell phenotype, B cell death and reduced immunoglobulin release.
    Davies FJ; Olme C; Lynskey NN; Turner CE; Sriskandan S
    Clin Exp Immunol; 2019 Jul; 197(1):83-94. PubMed ID: 30815853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Streptococcal pyrogenic exotoxin G gene in blood and pharyngeal isolates of Streptococcus dysgalactiae subspecies equisimilis has a limited role in pathogenesis.
    Korem M; Hidalgo-Grass C; Michael-Gayego A; Nir-Paz R; Salameh S; Moses AE
    J Microbiol Immunol Infect; 2014 Aug; 47(4):292-6. PubMed ID: 23380619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
    Pandey M; Mortensen R; Calcutt A; Powell J; Batzloff MR; Dietrich J; Good MF
    J Immunol; 2016 Apr; 196(8):3364-74. PubMed ID: 26969753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation.
    Arad G; Levy R; Hillman D; Kaempfer R
    Nat Med; 2000 Apr; 6(4):414-21. PubMed ID: 10742148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo efficacy of a chimeric peptide derived from the conserved region of the M protein against group C and G streptococci.
    Nordström T; Malcolm J; Magor G; Good MF; Batzloff MR
    Clin Vaccine Immunol; 2012 Dec; 19(12):1984-7. PubMed ID: 23081813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human leukocyte antigen class II haplotypes that protect against or predispose to streptococcal toxic shock.
    Llewelyn M
    Clin Infect Dis; 2005 Nov; 41 Suppl 7():S445-8. PubMed ID: 16237645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA transgenic mice provide evidence for a direct and dominant role of HLA class II variation in modulating the severity of streptococcal sepsis.
    Nooh MM; El-Gengehi N; Kansal R; David CS; Kotb M
    J Immunol; 2007 Mar; 178(5):3076-83. PubMed ID: 17312154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad-spectrum immunity against superantigens is elicited in mice protected from lethal shock by a superantigen antagonist peptide.
    Arad G; Hillman D; Levy R; Kaempfer R
    Immunol Lett; 2004 Feb; 91(2-3):141-5. PubMed ID: 15019282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome.
    Eriksson BK; Andersson J; Holm SE; Norgren M
    J Infect Dis; 1999 Aug; 180(2):410-8. PubMed ID: 10395857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
    Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
    Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.